June 18, 2025 02:17 PM EDT
R&D

Zealand study shows high­er GLP-1/GLP-2 dos­es may lead to greater weight loss

Max Gelman

Senior Editor

Zealand Phar­ma on Wednes­day rolled out more Phase 1b da­ta for its ex­per­i­men­tal GLP-1/GLP-2 drug, show­ing that high­er dos­es could lead to more weight loss …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Gilead gets ground­break­ing FDA ap­proval for twice-year­ly HIV pre­ven­tion shot 

How a tai­lored ALS drug could help broad­en rare dis­ease ther­a­pies

Grail shares jump on study re­sults for can­cer test

Schol­ar Rock’s mus­cle-pre­serv­ing obe­si­ty drug add-on looks com­pet­i­tive

CBER head Prasad adds chief med­ical and sci­en­tif­ic of­fi­cer to his ti­tle

sponsored

This com­pa­ny has spent a decade in­no­vat­ing NGS-based com­pan­ion di­ag­nos­tics world­wide–what’s next?

A service from the Financial Times